.Pharmacolibrary.Drugs.R_RespiratorySystem.R07A_OtherRespiratorySystemProducts.R07AX01_NitricOxide.NitricOxide .Pharmacolibrary.Drugs.R_RespiratorySystem.R07A_OtherRespiratorySystemProducts.R07AX01_NitricOxide.NitricOxide| name: | NitricOxide |
| ATC code: | R07AX01 | route: | inhalation |
| n-compartments | 1 |
Nitric oxide is an inhaled gas approved for the treatment of hypoxic respiratory failure in neonates and infants with pulmonary hypertension. It acts as a selective pulmonary vasodilator, improving oxygenation and decreasing the need for extracorporeal membrane oxygenation. Due to its short half-life and rapid inactivation by hemoglobin, it acts locally in the pulmonary vasculature. Nitric oxide is not used orally or intravenously, and its clinical administration is limited to controlled inhalation.
Pharmacokinetic parameters are primarily determined in neonates and young children with pulmonary hypertension receiving inhaled nitric oxide; data derived from clinical use and PK estimates.
Bateman, RM, et al., & Prandi, E (2016). 36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016. Critical care (London, England) 20(Suppl 2) 94–None. DOI:10.1186/s13054-016-1208-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27885969
Bjermer, L (2011). Targeting small airways, a step further in asthma management. The clinical respiratory journal 5(3) 131–135. DOI:10.1111/j.1752-699X.2011.00240.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/21501394
Tamada, T, et al., & Ichinose, M (2015). Biomarker-based detection of asthma-COPD overlap syndrome in COPD populations. International journal of chronic obstructive pulmonary disease 10 2169–2176. DOI:10.2147/COPD.S88274 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26491283